Invesaro

Stocks Comparison

Medifast vs McCormick: revenue, profit, margins and growth compared

Medifast brought in $385.8M of revenue in fiscal 2025, McCormick $6.8B in fiscal 2025. Revenue changed by -36.0% at Medifast and +1.7% at McCormick on the year before, so McCormick grew faster. Medifast kept -4.8% of its revenue as net profit, McCormick 11.5%. Free cash flow was $1.2M at Medifast and $740.4M at McCormick.

Open the MED pageOpen the MKC page

Side by side, latest fiscal year

MEDMKC
Fiscal year endedFY2025 (December 31, 2025)FY2025 (November 30, 2025)
Revenue$385.8M$6.8B
Revenue growth-36.0%+1.7%
Net income-$18.7M$789.4M
Net margin-4.8%11.5%
Free cash flow$1.2M$740.4M
Free cash flow margin0.3%10.8%
Earnings per share (diluted)-$1.70$2.93
Cash$89.3M$95.9M
Debtn/a$3.6B
Price to earningsn/a16.4
Market value$136.1M$12.9B
Dividend yieldn/a3.82%
Rank by revenue in sector#69 of 93 · Consumer staples#32 of 93 · Consumer staples

Over the years

Revenue
MED FY2018: $501MMED FY2019: $713.7MMED FY2020: $934.8MMED FY2021: $1.5BMED FY2022: $1.6BMED FY2023: $1.1BMED FY2024: $602.5MMED FY2025: $385.8MMKC FY2018: $5.3BMKC FY2019: $5.3BMKC FY2020: $5.6BMKC FY2021: $6.3BMKC FY2022: $6.4BMKC FY2023: $6.7BMKC FY2024: $6.7BMKC FY2025: $6.8BFY18FY19FY20FY21FY22FY23FY24FY25
MED $385.8MMKC $6.8B
Net income
MED FY2018: $55.8MMED FY2019: $77.9MMED FY2020: $102.9MMED FY2021: $164MMED FY2022: $143.6MMED FY2023: $99.4MMED FY2024: $2.1MMED FY2025: -$18.7MMKC FY2018: $933.4MMKC FY2019: $702.7MMKC FY2020: $747.4MMKC FY2021: $755.3MMKC FY2022: $682MMKC FY2023: $680.6MMKC FY2024: $788.5MMKC FY2025: $789.4MFY18FY19FY20FY21FY22FY23FY24FY25
MED -$18.7MMKC $789.4M
Net margin
MED FY2018: 11.1%MED FY2019: 10.9%MED FY2020: 11.0%MED FY2021: 10.7%MED FY2022: 9.0%MED FY2023: 9.3%MED FY2024: 0.3%MED FY2025: -4.8%MKC FY2018: 17.6%MKC FY2019: 13.1%MKC FY2020: 13.3%MKC FY2021: 12.0%MKC FY2022: 10.7%MKC FY2023: 10.2%MKC FY2024: 11.7%MKC FY2025: 11.5%FY18FY19FY20FY21FY22FY23FY24FY25
MED -4.8%MKC 11.5%
Revenue growth
MED FY2019: +42.4%MED FY2020: +31.0%MED FY2021: +63.2%MED FY2022: +4.8%MED FY2023: -32.9%MED FY2024: -43.8%MED FY2025: -36.0%MKC FY2019: +0.8%MKC FY2020: +4.7%MKC FY2021: +12.8%MKC FY2022: +0.5%MKC FY2023: +4.9%MKC FY2024: +0.9%MKC FY2025: +1.7%FY19FY20FY21FY22FY23FY24FY25
MED -36.0%MKC +1.7%
Free cash flow
MED FY2018: $55.9MMED FY2019: $74.2MMED FY2020: $139.3MMED FY2021: $60.3MMED FY2022: $177.9MMED FY2023: $141.2MMED FY2024: $17MMED FY2025: $1.2MMKC FY2018: $652.1MMKC FY2019: $773.1MMKC FY2020: $816MMKC FY2021: $550.3MMKC FY2022: $389.5MMKC FY2023: $973.4MMKC FY2024: $647MMKC FY2025: $740.4MFY18FY19FY20FY21FY22FY23FY24FY25
MED $1.2MMKC $740.4M

Fiscal years as each company reports them; the two may end in different months.

Questions about Medifast and McCormick

Which is bigger by revenue, Medifast or McCormick?

McCormick is bigger by revenue: $6.8B in fiscal 2025, against $385.8M for Medifast in fiscal 2025.

Which keeps more of its revenue as profit, Medifast or McCormick?

Medifast had a net margin of -4.8% in fiscal 2025; McCormick had 11.5% in fiscal 2025.

Which grew revenue faster, Medifast or McCormick?

In their latest fiscal years revenue changed by -36.0% at Medifast and +1.7% at McCormick.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

MED vs UTZ
MED vs TWG
MKC vs UTZ
MKC vs TWG

Compare more companies